AML originates from a rare population of cells, termed leukemic stem cells (LSCs) or leukemia-initiating cells, which are capable of self-renewal, proliferation and differentiation into malignant ...
Clinical Trials Arena on MSN2d
Cantargia enrols first patient in trial of nadunolimab for AML and MDSSwedish company Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals ...
4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells ... of acute myeloid leukemia and ...
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2025/Personalisierte+The... https://tu-dresden.de/med/mf/die-fakultaet/newsuebersicht/personalisierte-therap ...
NextCure (NASDAQ:NXTC – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, ...
5don MSN
A single molecular switch is essential for blood stem cells to enter an activated, regenerative state in which they produce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback